Efficacy and Safety of Ainuovirine Treating With AIDS Patients
Sponsored by Guangzhou 8th People's Hospital
About this trial
Last updated 3 years ago
Study ID
X220314682
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18 to 60 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 3 years ago
What is this trial about?
Ainuovirine is the third generation of non nucleoside reverse transcriptase
inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical
studies show that Ainuovirine is safe and potent, it solves the problem from the
first-generation NNRTIs such as Efavirenz with large side effects and the
second-generation like Rilpivirine not suitable for high viral load, but there are no
relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected
patients in China so far. This project aims to explore the efficacy and safety of ART
regimens containing Ainuovirine for HIV-infected patients in real clinical environment,
in further to guide clinical application.
What are the participation requirements?
Inclusion Criteria
Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign informed consent
Exclusion Criteria
1. Patients who are participating in other interventional clinical trials; 2. Patients who previously participated in the ACC007 study.
Locations
Location
Status
Recruiting